Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men.

Veldhuis JD, Bidlingmaier M, Anderson SM, Evans WS, Wu Z, Strasburger CJ

The Journal of clinical endocrinology and metabolism1 Dec 2002Cited by 48 (Europe PMC)

PMID12466380DOI10.1210/jc.2001-011885PepBankPUB-12466380

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialMechanism
In healthy adults, pegvisomant reduced total IGF-I by 34% versus placebo, from 257 +/- 37 to 170 +/- 24 micro g/liter (P < 0.001).
In plain wordsIn healthy adults, pegvisomant reduced total IGF-I versus placebo.
Peptide
Pegvisomant
Outcome
DecreaseSerum total IGF-I
Study
n = 16
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 mg/kg, single injection · subcutaneousAs given in this study (human).
Measurements
Total IGF-I
170 micro g/liter
pegvisomant
Total IGF-I
257 micro g/liter
placebo
Total IGF-I reduction
34%
pegvisomant versus placebo
Source sentences
Summary
Inhibitory efficacy of the GH receptor antagonist peptide was affirmed by way of a 34% reduction in the serum total IGF-I concentration, i.e., from 257 +/- 37 (placebo) to 170 +/- 24 (drug) micro g/liter (P < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy young adults (nine men and seven women) participated in a double-blind, prospectively randomized, within-subject cross-over study.
Summary · context
The intervention comprised a single sc injection of placebo vs. a high dose of pegvisomant (1 mg/kg sc) timed 62 and 74 h before the overnight sampling and daytime infusion sessions, respectively.
Report a problemFND-1246638002
02HumanRandomized controlled trialMechanism
In healthy adults, pegvisomant increased mean GH by 77% versus placebo, from 1.3 +/- 0.23 to 2.3 +/- 0.42 micro g/liter (P = 0.003).
In plain wordsIn healthy adults, pegvisomant increased mean GH versus placebo.
Peptide
Pegvisomant
Outcome
IncreaseMean GH concentration
Study
n = 16
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 mg/kg, single injection · subcutaneousAs given in this study (human).
Measurements
Mean GH
2.3 micro g/liter
pegvisomant
Mean GH
1.3 micro g/liter
placebo
Mean GH increase
77%
pegvisomant versus placebo
Source sentences
Summary
and a reciprocal 77% elevation of the (10-h) mean GH concentration, i.e., from 1.3 +/- 0.23 (placebo) to 2.3 +/- 0.42 (drug) micro g/liter (P = 0.003).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy young adults (nine men and seven women) participated in a double-blind, prospectively randomized, within-subject cross-over study.
Summary · context
The intervention comprised a single sc injection of placebo vs. a high dose of pegvisomant (1 mg/kg sc) timed 62 and 74 h before the overnight sampling and daytime infusion sessions, respectively.
Report a problemFND-1246638003
03HumanRandomized controlled trialMechanism
In healthy adults, secreted GH half-life was 14 +/- 0.69 minutes with pegvisomant versus 15 +/- 1.3 with placebo, without a significant difference.
In plain wordsIn healthy adults, pegvisomant did not significantly change secreted GH half-life versus placebo.
Peptide
Pegvisomant
Outcome
No significant changeSecreted GH half-life
Study
n = 16
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 mg/kg, single injection · subcutaneousAs given in this study (human).
Measurements
Secreted GH half-life
14 minutes
pegvisomant
Secreted GH half-life
15 minutes
placebo
Source sentences
Summary
ANOVA disclosed that prior administration of pegvisomant (compared with placebo) did not alter: 1) the calculated half-life (minutes) of secreted GH, which averaged 15 +/- 1.3 (placebo) and 14 +/- 0.69 (drug)
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy young adults (nine men and seven women) participated in a double-blind, prospectively randomized, within-subject cross-over study.
Summary · context
The intervention comprised a single sc injection of placebo vs. a high dose of pegvisomant (1 mg/kg sc) timed 62 and 74 h before the overnight sampling and daytime infusion sessions, respectively.
Report a problemFND-1246638004
04HumanRandomized controlled trialMechanism
In healthy adults, injected rhGH disappearance half-time was 13 +/- 0.5 minutes with pegvisomant versus 15 +/- 1.0 with placebo, without a significant difference.
In plain wordsIn healthy adults, pegvisomant did not significantly change injected rhGH disappearance half-time versus placebo.
Peptide
Pegvisomant
Outcome
No significant changeInjected rhGH disappearance half-time
Study
n = 16
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 mg/kg, single injection · subcutaneousAs given in this study (human).
Measurements
rhGH disappearance half-time
13 minutes
pegvisomant, 10 micro g/kg rhGH pulse
rhGH disappearance half-time
15 minutes
placebo, 10 micro g/kg rhGH pulse
Source sentences
Summary
2) the half-time of disappearance (minutes) of an iv pulse of rhGH, 15 +/- 1.0 (placebo) and 13 +/- 0.5 (drug) (for the 10 micro g/kg dose)
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy young adults (nine men and seven women) participated in a double-blind, prospectively randomized, within-subject cross-over study.
Summary · context
The intervention comprised a single sc injection of placebo vs. a high dose of pegvisomant (1 mg/kg sc) timed 62 and 74 h before the overnight sampling and daytime infusion sessions, respectively.
Report a problemFND-1246638005
05HumanRandomized controlled trialMechanism
In healthy adults, rhGH distribution volume was 58 +/- 3.5 with pegvisomant versus 59 +/- 6.2 milliliters per kilogram with placebo, without significant change.
In plain wordsIn healthy adults, pegvisomant did not significantly change rhGH distribution volume versus placebo.
Peptide
Pegvisomant
Outcome
No significant changerhGH distribution volume
Study
n = 16
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 mg/kg, single injection · subcutaneousAs given in this study (human).
Measurements
rhGH distribution volume
58 milliliters per kilogram
pegvisomant
rhGH distribution volume
59 milliliters per kilogram
placebo
Source sentences
Summary
3) the distribution volume (milliliters per kilogram) of rhGH, 59 +/- 6.2 (placebo) and 58 +/- 3.5 (drug)
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy young adults (nine men and seven women) participated in a double-blind, prospectively randomized, within-subject cross-over study.
Summary · context
The intervention comprised a single sc injection of placebo vs. a high dose of pegvisomant (1 mg/kg sc) timed 62 and 74 h before the overnight sampling and daytime infusion sessions, respectively.
Report a problemFND-1246638006
06HumanRandomized controlled trialMechanism
In healthy adults, steady state GH was 18.3 +/- 2.3 with pegvisomant versus 18.2 +/- 2.4 micrograms per liter with placebo, without significant change.
In plain wordsIn healthy adults, pegvisomant did not significantly change steady state GH versus placebo.
Peptide
Pegvisomant
Outcome
No significant changeSteady state GH concentration
Study
n = 16
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 mg/kg, single injection · subcutaneousAs given in this study (human).
Measurements
Steady state GH concentration
18.3 micrograms per liter
pegvisomant, constant rhGH infusion 5 micro g/kg every 2 h
Steady state GH concentration
18.2 micrograms per liter
placebo, constant rhGH infusion 5 micro g/kg every 2 h
Source sentences
Summary
4) the steady state GH concentration (micrograms per liter) attained during constant iv infusion of rhGH (at a rate of 5 micro g/kg every 2 h), 18.2 +/- 2.4 (placebo) and 18.3 +/- 2.3 (drug)
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy young adults (nine men and seven women) participated in a double-blind, prospectively randomized, within-subject cross-over study.
Summary · context
The intervention comprised a single sc injection of placebo vs. a high dose of pegvisomant (1 mg/kg sc) timed 62 and 74 h before the overnight sampling and daytime infusion sessions, respectively.
Report a problemFND-1246638007
07HumanRandomized controlled trialMechanism
In healthy adults, GH elimination half-life was 16 +/- 1.8 minutes with pegvisomant versus 16 +/- 0.98 with placebo, without significant change.
In plain wordsIn healthy adults, pegvisomant did not significantly change GH elimination half-life versus placebo.
Peptide
Pegvisomant
Outcome
No significant changeGH elimination half-life
Study
n = 16
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 mg/kg, single injection · subcutaneousAs given in this study (human).
Measurements
GH elimination half-life from equilibrium
16 minutes
placebo (+/- 0.98)
GH elimination half-life from equilibrium
16 minutes
pegvisomant (+/- 1.8)
Source sentences
Summary
5) the half-life (minutes) of elimination of GH from equilibrium, 16 +/- 0.98 (placebo) and 16 +/- 1.8 (drug)
3 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy young adults (nine men and seven women) participated in a double-blind, prospectively randomized, within-subject cross-over study.
Summary · context
The intervention comprised a single sc injection of placebo vs. a high dose of pegvisomant (1 mg/kg sc) timed 62 and 74 h before the overnight sampling and daytime infusion sessions, respectively.
Summary · context
ANOVA disclosed that prior administration of pegvisomant (compared with placebo) did not alter:
Report a problemFND-1246638008
08HumanRandomized controlled trialMechanism
In healthy adults, rhGH clearance was 3.5 +/- 0.31 with pegvisomant versus 3.8 +/- 0.32 liters per kilogram per day with placebo, without significant change.
In plain wordsIn healthy adults, pegvisomant did not significantly change rhGH clearance versus placebo.
Peptide
Pegvisomant
Outcome
No significant changerhGH metabolic clearance rate
Study
n = 16
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 mg/kg, single injection · subcutaneousAs given in this study (human).
Measurements
Steady state rhGH metabolic clearance rate
3.8 liters per kilogram per day
placebo (+/- 0.32)
Steady state rhGH metabolic clearance rate
3.5 liters per kilogram per day
pegvisomant (+/- 0.31)
Source sentences
Summary
6) the steady state MCR (liters per kilogram per day) of rhGH, 3.8 +/- 0.32 (placebo) and 3.5 +/- 0.31 (drug).
3 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy young adults (nine men and seven women) participated in a double-blind, prospectively randomized, within-subject cross-over study.
Summary · context
The intervention comprised a single sc injection of placebo vs. a high dose of pegvisomant (1 mg/kg sc) timed 62 and 74 h before the overnight sampling and daytime infusion sessions, respectively.
Summary · context
ANOVA disclosed that prior administration of pegvisomant (compared with placebo) did not alter:
Report a problemFND-1246638009
09HumanNon-randomized trialPharmacokinetics
In healthy adults, pegvisomant concentrations averaged 4860 +/- 480 micro g/liter across the infusion interval, exceeding low steady state GH concentrations by 3000-fold.
In plain wordsIn healthy adults, pegvisomant concentrations averaged 4860 micro g/liter across the infusion interval.
Peptide
Pegvisomant
Outcome
Not applicablePegvisomant concentration
Study
n = 16
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1 mg/kg, single injection · subcutaneousAs given in this study (human).
Measurements
Pegvisomant concentration
4860 micro g/liter
mean across the infusion interval
Fold above low steady state GH concentration
3000 fold
pegvisomant versus GH
Source sentences
Summary
Pegvisomant concentrations averaged 4860 +/- 480 micro g/liter (+/-SEM) across the infusion interval, thus exceeding low steady state GH concentrations by 3000-fold.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixteen healthy young adults (nine men and seven women) participated in a double-blind, prospectively randomized, within-subject cross-over study.
Summary · context
The intervention comprised a single sc injection of placebo vs. a high dose of pegvisomant (1 mg/kg sc) timed 62 and 74 h before the overnight sampling and daytime infusion sessions, respectively.
Report a problemFND-1246638001

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT01804413

Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency

Oregon Health and Science Universityn = 10Mar 2011 to est. Dec 2013

Adults Growth Hormone Deficiency.

Trial page ClinicalTrials.govUpdated 24 Oct 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.